Hemocompatibility of drug-eluting coronary stents coated with sulfonated poly (styrene-block-isobutylene-block-styrene)

Department of Cardiology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
Biomaterials (Impact Factor: 8.31). 08/2012; 33(33):8204-12. DOI: 10.1016/j.biomaterials.2012.07.066
Source: PubMed

ABSTRACT The presence of polymer coating on a coronary stent is a major mediator of coronary inflammation reaction thereby affects re-endothelialization. Poly(styrene-block-isobutylene-block-styrene) (SIBS) is one of the most attractive alternatives to serve as stent coating, but has shown less than optimal biocompatibility. Increasing the sulfonic acid content in the polymer can result in increased strength and hydrophilicity. The present study was undertaken to determine the mechanism of action and in vivo efficacy of sulfonated SIBS (S-SIBS) designed specifically as a stent polymer with reduced inflammatory potential and greater endothelialization preservation potential. The blood compatibility of S-SIBS in vitro and its ability to support the attachment of human umbilical vein endothelial cells (HUVECs) were first assessed to get some insight into its potential use in vivo. Baer metal stent (BMS), S-SIBS-coated stent without drug (BMS Plus S-SIBS), standard drug-eluting stent (DES) and S-SIBS-coated drug-eluting stent (DES Plus S-SIBS) were then implanted in the coronary arteries of a porcine model. Neointimal hyperplasia was evaluated at 28 and 180 days, and re-endothelialization was evaluated at 7 and 28 days post stents implantation. The results showed that DES Plus S-SIBS exhibited similar ability to reduce neointimal hyperplasia but preserved endothelialization compared with standard DES. These results suggest potentially promising performance of S-SIBS-coated stent in human clinical applications of coronary stenting.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular implants find wide clinical applications, making a great contribution to the treatment of cardiovascular diseases. Such devices, endovascular stents, artificial vascular grafts, prosthetic heart valves to name a few typical examples, have been the mainstay of cardiovascular surgery. However, failure cases of the implants still exist, which urge us to understand what has happened at the blood-contacting interface and how the tissues have responded during the post-implantation period. Aiming to eliminate these pathological events, various approaches of surface modification of the cardiovascular devices have been used in order to improve hemocompatibility and cytocompatibility. In this review, the blood-biomaterial interfacial events and the evolution of the surface modification strategies are discussed, together with the recent developments on the surface modification of cardiovascular materials like biomimetic extracellular matrix and accelerated endothelialization. These novel surface modification strategies open a new chapter on designing ideal blood-friendly implantable materials. (C) 2013 Published by Elsevier B.V.
    Surface and Coatings Technology 10/2013; 233:80-90. DOI:10.1016/j.surfcoat.2013.02.008 · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The biostable poly(styrene-b-isobutylene-b-styrene) (SIBS) elastomers are well-known for their large-scale in vivo application as drug-eluting coatings in coronary stents. In this study, the SIBS elastomers were modified with a poly(dopamine) (PDA) adherent layer, followed by integrating both chitosan (CS) and hyaluronic acid (HA) onto their surfaces. The as-prepared samples (SIBS-CS-g-HA) presented excellent cytocompatibility because CS facilitates cell attachment and HA enhances cell proliferation. The initial adhesion test of E. coli on SIBS-CS-g-HA showed effective antiadhesive properties. The in vitro antibacterial test confirmed that SIBS-CS-g-HA has good antibacterial activity.
    RSC Advances 01/2014; 4(59):31481. DOI:10.1039/C4RA04523H · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zwitterionic hyperbranched polyester (HBPE) synthesized on bare metal stents (BMS) surface by surface-initiated atom transfer radical polymerization (SI-ATRP) method. The modified BMS obtained was tested for its blood compatibility. The blood compatibility studies were including, platelet adhesion tests, hemolysis assay, morphological changes in RBCs, coagulation tests, PRT assay, complement activation, platelet activation, and the cytotoxicity was also investigated. The modified BMS surface does not cause platelets adherent, red blood cell disruption, hemolysis and does not induce complement and platelets activation. All results indicated that the modified BMS was blood compatible and no cytotoxicity. It has the potential use for biomedical applications.
    Journal of Colloid and Interface Science 04/2014; 420:88–96. DOI:10.1016/j.jcis.2014.01.016 · 3.55 Impact Factor